Bayer's magic formula in Singapore - open collaboration
Public-private partnerships the key, especially in clinical research' spending S$27 million over 10 years
Singapore
BAYER'S absence last year from an industry manufacturing consortium did not mean that it snubbed partnerships in the Republic, said the German giant's top drugs man here.
Claus Zieler, Bayer Pharmaceuticals' senior vice-president and head of commercial operations in the Asia-Pacific, told The Business Times that the company is open to tie-ups, including in the private sector.
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Oil settles higher on supply concerns in the Mid-East, economic woes subdue gains
S-Reits falter as investors weigh possibility of zero rate cuts in 2024
CapitaLand Investment posts total revenue of S$650 million for Q1
Europe: Stoxx 600 logs best day in three months as banks shine
US: Stocks rally after strong tech results
Porsche posts Q1 profit drop on ramp-up costs